Preferred Label : Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318;
NCIt synonyms : Anti-PD-1/PD-L1 Bispecific Antibody IBI318; Recombinant Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318; Bispecific Antibody IBI318;
NCIt definition : A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human
negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1;
PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with
potential checkpoint inhibitory, immunostimulating and antineoplastic activities.
Upon administration, anti-PD-1/anti-PD-L1 bispecific antibody IBI318 simultaneously
targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including
activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1, which is expressed
on tumor cells. This crosslinks PD-1-expressing T cells and PD-L1-expressing tumor
cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits
the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This
abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances
cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor
growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival
of CD8-positive T-cells, suppresses the immune system and results in immune evasion.;
Molecule name : IBI 318; IBI-318;
NCI Metathesaurus CUI : CL1405902;
Origin ID : C171938;
UMLS CUI : C5417882;
Semantic type(s)
- concept_is_in_subset
